Nonvitamin K antagonist oral anticoagulants (NOACs): the tide continues to come in
Open Access
- 1 August 2015
- journal article
- editorial
- Published by Taylor & Francis in Vascular Health and Risk Management
- Vol. ume 11, 489-492
Abstract
Nonvitamin K antagonist oral anticoagulants (NOACs): the tide continues to come in Andrew Blann University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UKThrombosis is the major common endpoint in most human diseases. In the coronary circulation, occlusive thrombi and/or the rupture of atherosclerotic plaque causes myocardial infarction, and in the cerebral circulation thrombosis, causes ischemic stroke. In the venous circulation, venous thromboembolism (VTE), manifesting clinically as pulmonary embolus and deep vein thrombosis (DVT), is a frequent complication among inpatients, and contributes to longer hospital stays with increased morbidity and mortality. Until perhaps 5 years ago, heparinoids (unfractionated heparin, low molecular weight heparin [LMWH], and fondaparinux) and vitamin K antagonists (VKAs: warfarin, acenocoumarol, phenocoumarol) were the only options for the prevention of thrombotic stroke in atrial fibrillation, and of VTE in general. Although effective, these traditional drugs have several practical, management, and clinical disadvantages, a fact that our colleagues in industry have not been slow to recognize and address by developing improved drugs, now collectively known as nonvitamin K antagonist oral anti coagulants (NOACs). These agents are steadily replacing the heparinoids and VKAs in both inpatient and outpatient prevention and treatment of thrombosis.Keywords
This publication has 35 references indexed in Scilit:
- Reversal of anticoagulants: an overview of current developmentsThrombosis and Haemostasis, 2015
- A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatranThrombosis and Haemostasis, 2015
- Pros and Cons of Vitamin K Antagonists and Non–Vitamin K Antagonist Oral AnticoagulantsSeminars in Thrombosis and Hemostasis, 2015
- Evaluation of the oral direct factor Xa inhibitor – betrixabanExpert Opinion on Investigational Drugs, 2013
- Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxabanClinical Research in Cardiology, 2013
- Darexaban for the Prevention of Venous Thromboembolism in Asian Patients Undergoing Orthopedic SurgeryClinical and Applied Thrombosis/Hemostasis, 2012
- Darexaban (YM150) prevents venous thromboembolism in Japanese patients undergoing major abdominal surgery: Phase III randomized, mechanical prophylaxis-controlled, open-label studyThrombosis Research, 2012
- Rivaroxaban in Patients with a Recent Acute Coronary SyndromeNew England Journal of Medicine, 2012
- The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjectsBritish Journal of Clinical Pharmacology, 2007
- Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitorClinical Pharmacology & Therapeutics, 2005